Have a feature idea you'd love to see implemented?
Let us know!
MRVI Maravai Lifesciences Holdings Inc
Price (delayed)
$5.61
Market cap
$1.42B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$1.39B
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are
Highlights
Maravai Lifesciences Holdings's quick ratio has increased by 20% YoY and by 8% QoQ
MRVI's net income has dropped by 70% since the previous quarter
Maravai Lifesciences Holdings's EPS has plunged by 66% from the previous quarter
Key stats
What are the main financial stats of MRVI
Market
Valuations
Earnings
Shares outstanding
252.53M
Market cap
$1.42B
Enterprise value
$1.39B
Price to book (P/B)
4.1
Price to sales (P/S)
2.87
EV/EBIT
2.35
EV/EBITDA
2.15
EV/Sales
5.03
Revenue
$276.92M
Gross profit
$128.38M
Net income
-$224.66M
EBIT
$591.49M
EBITDA
$646.81M
Free cash flow
-$1.4M
Per share
Balance sheet
Liquidity
EPS
-$1.64
EPS diluted
-$1.64
Free cash flow per share
-$0.01
Book value per share
$1.37
Revenue per share
$1.96
TBVPS
$6.39
Total assets
$1.28B
Total liabilities
$665.09M
Debt
$553.8M
Equity
$345.14M
Working capital
$615.86M
Debt to equity
1.6
Current ratio
10.74
Quick ratio
9.6
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
233.6%
Gross margin
46.4%
Net margin
-81.1%
Operating margin
-75.6%
Return on assets
-15.9%
Return on equity
-55.8%
Return on invested capital
71.3%
Return on capital employed
48.7%
Return on sales
213.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRVI stock price
How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
5.25%
1 week
3.31%
1 month
-0.18%
1 year
-15.51%
YTD
-14.35%
QTD
-32.49%
Financial performance
How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$276.92M
Gross profit
$128.38M
Operating income
-$209.37M
Net income
-$224.66M
Gross margin
46.4%
Net margin
-81.1%
The company's net margin has shrunk by 71% QoQ
MRVI's net income has dropped by 70% since the previous quarter
Maravai Lifesciences Holdings's gross profit has decreased by 49% YoY
Maravai Lifesciences Holdings's revenue has decreased by 34% YoY
Growth
What is Maravai Lifesciences Holdings's growth rate over time
Valuation
What is Maravai Lifesciences Holdings stock price valuation
P/E
N/A
P/B
4.1
P/S
2.87
EV/EBIT
2.35
EV/EBITDA
2.15
EV/Sales
5.03
Maravai Lifesciences Holdings's EPS has plunged by 66% from the previous quarter
MRVI's price to book (P/B) is 84% less than its 5-year quarterly average of 24.4 and 20% less than its last 4 quarters average of 4.9
The company's equity fell by 34% YoY and by 21% QoQ
The price to sales (P/S) is 40% less than the 5-year quarterly average of 4.5 and 26% less than the last 4 quarters average of 3.7
Maravai Lifesciences Holdings's revenue has decreased by 34% YoY
Efficiency
How efficient is Maravai Lifesciences Holdings business performance
The return on assets has dropped by 101% since the previous quarter
The return on equity has dropped by 89% since the previous quarter
Maravai Lifesciences Holdings's ROS has decreased by 12% from the previous quarter
The company's return on invested capital rose by 9% QoQ
Dividends
What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRVI.
Financial health
How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 92% greater than its total liabilities
The total liabilities has plunged by 52% YoY
MRVI's total assets is down by 44% year-on-year and by 12% since the previous quarter
The company's debt is 60% higher than its equity
Maravai Lifesciences Holdings's debt to equity has increased by 50% YoY and by 26% QoQ
The company's equity fell by 34% YoY and by 21% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.